Category NEWS

ImmunityBio

ImmunityBio Secures Exclusive U.S. Deal with Japan BCG Laboratory to Expand Tokyo Strain BCG Supply

ImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United States ImmunityBio, Inc. a commercial-stage immunotherapy company, announced an exclusive U.S. Development and Supply Agreement with Japan BCG…

Read MoreImmunityBio Secures Exclusive U.S. Deal with Japan BCG Laboratory to Expand Tokyo Strain BCG Supply

OBIO® and IPON Renew Multi-Year Partnership to Strengthen Ontario’s Sovereign IP Capacity

OBIO® and IPON Renew Multi-Year Collaboration to Advance Ontario’s Sovereign IP Capacity OBIO® and Intellectual Property Ontario (IPON) have renewed their memorandum of understanding (MOU) to ensure that Ontario’s next generation of companies developing innovative human health products continue to access optimal…

Read MoreOBIO® and IPON Renew Multi-Year Partnership to Strengthen Ontario’s Sovereign IP Capacity
IQVIA

IQVIA and Kexing Biopharm Expand AI-Driven Collaboration to Accelerate Global Biosimilar Development

IQVIA and Kexing Biopharm Expand Strategic Collaboration to Accelerate Global Biosimilar Development using AI-Enabled Capabilities IQVIA a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, is advancing its strategic…

Read MoreIQVIA and Kexing Biopharm Expand AI-Driven Collaboration to Accelerate Global Biosimilar Development
Next Health

Next Health Opens in Peoria, Bringing Advanced Longevity and Preventive Care Services to Arizona

Next Health in Peoria Hosting Grand Opening, Bringing Advanced Longevity & Preventive Health Services to Arizona Next Health, the world’s most advanced and comprehensive brand of health optimization and longevity centers, invites the community and media to its newest location in…

Read MoreNext Health Opens in Peoria, Bringing Advanced Longevity and Preventive Care Services to Arizona
Bristol Myers

Bristol Myers Squibb Receives EU Approval for Sotyktu in Adults With Active Psoriatic Arthritis

Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults Bristol Myers Squibb announced that the European Commission has granted approval to Sotyktu (deucravacitinib), alone or in combination with methotrexate, for the treatment of active…

Read MoreBristol Myers Squibb Receives EU Approval for Sotyktu in Adults With Active Psoriatic Arthritis
Chemical

Chemical Reduction Solutions expands partnership with Simoniz USA to commercialize nanobubble technology in the car wash industry

Chemical Reduction Solutions LLC Expands Partnership with Simoniz USA Inc. to Exclusively Commercialize Nanobubble Technology in the Car Wash Industry Chemical Reduction Solutions LLC (“CRS”), a developer of hydrodynamic cavitation-based nanobubble technology, today announced an expanded partnership with Simoniz USA…

Read MoreChemical Reduction Solutions expands partnership with Simoniz USA to commercialize nanobubble technology in the car wash industry
Arrowhead

Arrowhead wins Australian approval for REDEMPLO® (plozasiran) for FCS treatment

Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO® (plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS) Arrowhead Pharmaceuticals, Inc. announced that the Australian Therapeutic Goods Administration (TGA) has approved REDEMPLO® (plozasiran), a small interfering RNA (siRNA) medicine,…

Read MoreArrowhead wins Australian approval for REDEMPLO® (plozasiran) for FCS treatment